|
|
- 2017
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacyDOI: 10.1016/j.trci.2017.04.003 Keywords: Alzheimer's disease, Amyloid β, Biomarkers, Cerebrospinal fluid, Immunotherapy, Monoclonal antibody, Pharmacokinetics, Pharmacodynamics, Phase-II study, Ponezumab Abstract: Multiple intravenous doses of ponezumab, an anti-amyloid antibody, were evaluated in subjects with mild-to-moderate Alzheimer's disease (AD)
|
